After years of setbacks, dementia researchers are getting excited about a new antibody drug called lecanemab. No one expects it to stop cognitive decline, but even slowing it would be a breakthrough
Analysis shows significant benefits with no major side-effects for mother or baby but more trials needed ‘to confirm results’• [Update: the study on which this article reports was later withdrawn by the BMJ owing to ‘fundamental flaws’ in the research – see footnote]